Juvenile Idiopathic Arthritis News and Research

RSS
Juvenile idiopathic arthritis (JIA) is the name given to a group of conditions characterized by joint inflammation or arthritis, occurring first before the age of 16.
U.Va. researchers named recipients of 2013 Hartwell Individual Biomedical Research Awards

U.Va. researchers named recipients of 2013 Hartwell Individual Biomedical Research Awards

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma announces launch of OTREXUP to Dermatologists

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

FDA approves OTREXUP injection for adults with RA, children with active pJIA

FDA approves OTREXUP injection for adults with RA, children with active pJIA

ACR journals publish guide that provides new treatments for children with systemic JIA

ACR journals publish guide that provides new treatments for children with systemic JIA

Study provides first genomic characterization of remission in juvenile rheumatoid arthritis patients

Study provides first genomic characterization of remission in juvenile rheumatoid arthritis patients

Joints of children with chronic inflammatory arthritis contain premature aging of immune cells

Joints of children with chronic inflammatory arthritis contain premature aging of immune cells

Baylor Research Institute, Novartis sign license agreement for canakinumab

Baylor Research Institute, Novartis sign license agreement for canakinumab

Researchers discover potential markers for severity of juvenile idiopathic arthritis

Researchers discover potential markers for severity of juvenile idiopathic arthritis

MMR booster does not result in worse JIA disease activity in children

MMR booster does not result in worse JIA disease activity in children

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

Arthritis estimated to cost $33 billion annually to the Canadian economy

Arthritis estimated to cost $33 billion annually to the Canadian economy

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Scientists identify new genes that offer potential treatment options for childhood arthritis

Scientists identify new genes that offer potential treatment options for childhood arthritis

Study: Total knee replacements in younger patients with juvenile arthritis last for 10 years

Study: Total knee replacements in younger patients with juvenile arthritis last for 10 years

Ceramic-on-ceramic hips good option for juvenile arthritis

Ceramic-on-ceramic hips good option for juvenile arthritis

Abbott receives FDA approval for Humira to treat ulcerative colitis

Abbott receives FDA approval for Humira to treat ulcerative colitis

Functional disability impacts educational attainment in children with JIA

Functional disability impacts educational attainment in children with JIA